Mexiletine labels and packages: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 19: | Line 19: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 15:47, 10 March 2014
| Mexiletine |
|---|
| MEXILETINE HYDROCHLORIDE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Mexiletine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]; Ahmed Zaghw, M.D. [3]
Labels And Packages
 |
 |
 |
.[1]
References
- ↑ "MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC]". Retrieved 3 March 2014.